Effects of (+/-) 3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans

Area of Science:

• Neuropharmacology
• Endocrinology
• Psychiatry

Background:

• 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a recreational drug with known psychoactive properties.
• Previous research suggests MDMA may affect neurotransmitter systems, including dopamine, but its impact on hormonal regulation requires further investigation.

Purpose of the Study:

• To investigate the effects of MDMA use on prolactin (PRL) and growth hormone (GH) responses to bromocriptine, a dopaminergic agonist.
• To explore the relationship between hormonal responses, psychometric measures, and the extent of MDMA exposure.

Main Methods:

• A study involving 12 MDMA users (Group A) and 12 control subjects (Group B) was conducted.
• Subjects underwent evaluation of PRL and GH responses to bromocriptine and completed psychometric assessments three weeks after MDMA cessation.
• Hormonal responses (AUCs) and psychometric scores were analyzed for correlations.

Main Results:

• Prolactin (PRL) responses to bromocriptine were similar between MDMA users and controls.
• Growth hormone (GH) responses to bromocriptine were significantly reduced in MDMA users compared to controls (P < 0.001).
• MDMA users exhibited higher scores in novelty seeking, aggressiveness, depression, and Hamilton Depression Rating Scale. GH AUCs inversely correlated with MDMA exposure (r = -0.48, P < 0.01).

Conclusions:

• Reduced GH response to bromocriptine in MDMA users may indicate decreased hypothalamic D2 receptor sensitivity, potentially due to increased dopamine.
• The inverse correlation between GH response and MDMA exposure suggests a direct pharmacological effect of MDMA on brain dopamine function.
• While premorbid dopaminergic changes cannot be ruled out, findings support MDMA's potential to alter dopamine system sensitivity.